Morgan Stanley resumed coverage on Pandion Therapeutics with a new price target
$PAND
Morgan Stanley resumed coverage of Pandion Therapeutics with a rating of Equal Weight and set a new price target of $60.00 from $25.00 previously
Save time and jump to the most important pieces.